MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS
Clinical trials for MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS trials appear
Sign up with your email to follow new studies for MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…
Matched conditions: MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for stomach cancer: immunotherapy combo targets resistant tumors
Disease control Not yet recruitingThis phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …
Matched conditions: MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Stomach cancer study may spare some patients unnecessary surgery
Knowledge-focused Not yet recruitingThis study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…
Matched conditions: MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC